SofWave Medical (SOFW) Q3 2024 earnings summary

Executive summary

• Q3 revenue was $13.507M, up 10.5% YoY; 9M revenue reached $41.333M, up 18%.

• Q3 recurring pulse revenue rose 72% YoY to $5.4M; 9M recurring pulse revenue increased 88% to $16.1M.

• 9M operating and net losses narrowed YoY; management forecast profitability for FY 2025 while noting operating profitability may not be reached in 2024.

Financial highlights

• Q3 gross profit was $10.156M, up from $8.920M; 9M gross profit was $31.218M, up from $25.830M.

• 9M operating loss narrowed to $3.484M from $7.826M; excluding stock-based compensation, it fell to $1.784M from $5.967M.

• 9M net loss was $3.843M versus $7.903M; Q3 net loss was $1.330M versus $1.235M.

• Q3 G&A included $0.5M in U.S. trademark-litigation legal expenses; excluding litigation costs, Q3 non-IFRS operating loss declined 62% YoY.

Outlook and guidance

• Management expects operating losses to continue narrowing and forecasts profitability for FY 2025; operating profitability may not be reached in 2024.

• Growth plans include global expansion, broader U.S. sales coverage, practice development specialists and digital brand-building.

• A lean, scalable infrastructure was described as supporting high growth and profitability.